Skip to main content

Advertisement

ADVERTISEMENT

Breast Cancer Videos

William J. Gradishar, MD
Videos
06/04/2024
William J. Gradishar, MD
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD,...
06/04/2024
Journal of Clinical Pathways
Reshma Mahtani, DO,  Terry Mamounas, MD, Jane Meisel, MD
Videos
02/15/2024
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of...
02/15/2024
Oncology
John A. Ingoglia, PharmD
Videos
10/31/2023

Featuring John A. Ingoglia, PharmD, BCOP, CPP

Featuring John A. Ingoglia, PharmD, B...
John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.
John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.
John A. Ingoglia, PharmD, BCOP,...
10/31/2023
Journal of Clinical Pathways

Advertisement

Dr Danielle Gentile.
Videos
07/12/2023

Featuring Danielle Gentile, PhD

Featuring Danielle Gentile, PhD ...
Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.
Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.
Danielle Gentile, PhD, a senior...
07/12/2023
Journal of Clinical Pathways
Sayeh Lavasani, MD, MS, FRCPC
Videos
10/16/2022
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC,...
10/16/2022
Journal of Clinical Pathways
Sara Tolaney, MD, MPH
Videos
08/03/2022
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses...
08/03/2022
Journal of Clinical Pathways

Advertisement

Shlomit Amar-Farkash, PhD, MSc
Videos
07/14/2022
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc,...
07/14/2022
Journal of Clinical Pathways
Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network
Videos
07/06/2022
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA,...
07/06/2022
Journal of Clinical Pathways
Ethan Sokol, PhD
Videos
10/21/2021
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses...
10/21/2021
Journal of Clinical Pathways

Advertisement

Weija Wang
Videos
05/27/2021
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...
Weijia Wang, MSc, discusses...
05/27/2021
Journal of Clinical Pathways

Advertisement